Replies to post #377525 on Elite Pharmaceuticals Inc (ELTP)

[namtae]

I agree, which makes why the CEO hasnt already applied for listing even more curious

Make no sense to stay on the OTC yet, here it is.. still

If theres a better explanation why ELTP is still on the otc, besides having something to hide like Mikah transactions, im all ears

[ko49]

Here's some research on reverse splits. As you can see it's not good for the investor.
"Researchers at the Stern School of Business at NYU and Emory University looked at more than 40 years of data, from 1962 to 2001, and found that of the 1,600 reverse splits, shares underperformed their non-split peers by 15.6% in the first year following the split, 36% in the second year and 54% in the third year."
https://www.cabotwealth.com/daily/stock-market/reverse-stock-splits-shareholders

[jour_trader]

Agree 100%. Lannett deal delays timing of when this would be possible. I think it pushes it out at least 18-24 months.

[Makai63]

I would wait until Elite has 4-5 cash cow products before uplisting. Having only Adderall (which in my opinion saved Elite's arse) is a huge success for Elite. Moving product will be slow at first, but the cost savings will also be huge. We need multiple $100M/yr products and be able to acquire 10% of each product. Then, we will be ready to uplist. Otherwise, buy low and hold.

[IB_]

A Nasdaq listing does not automatically equal institutional investors will go long ELTP shares !!!!!!!!!! Institutional investors are usually fairly diligent in their research on potential investment opportunities, which would leave one to wonder how they would view Elites CEO and his private pharma company Mikah being tied to a public company in which he controls !!!!!!!!!!!

I could see the potential for institutional investors to take a short position in ELTP post Nasdaq uplisting ??????????????????????

IB_